The number of patients who require maintenance on anticoagulation therapy (warfarin/Coumadin ®) for minimizing risk of cardiovascular events like stroke or thromboembolism is increasing.

Edoxaban was at least as effective as warfarin in preventing thromboembolism after bioprosthetic valve replacement in the ...

Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been ...

"Cadrenal Therapeutics has demonstrated a commitment to filling a serious gap in anticoagulation therapy," said Lisa Winget, Managing Editor at Pharma Tech Outlook. "We are pleased to recognize ...

In the ENBALV study, it was inconclusive whether edoxaban is a better treatment than warfarin for patients with early ...

(Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been recognized as the 2024 "Anticoagulation Therapy Company of ...

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure ...

Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the route of ...

Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

Introduction: Current guidelines recommend single anticoagulation (AC) therapy over combined AC plus anti-platelet (AP) therapy in patients with established cardiovascular disease (CVD) and ...

Community pharmacists can play an effective role in closing gaps in the delivery of stroke risk reduction therapy.